Henan Lingrui Pharmaceutical Co Ltd (600285) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Henan Lingrui Pharmaceutical Co Ltd (600285) has a cash flow conversion efficiency ratio of 0.043x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥140.12 Million ≈ $20.50 Million USD) by net assets (CN¥3.28 Billion ≈ $480.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Henan Lingrui Pharmaceutical Co Ltd to measure how many days the company can operate on defensive assets alone.
Henan Lingrui Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Henan Lingrui Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Henan Lingrui Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Henan Lingrui Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neinor Homes SLU
MC:HOME
|
0.154x |
|
Chongqing Three Gorges Water Conservancy and Electric Power Co Ltd
SHG:600116
|
0.048x |
|
Three's Company Media Group Co Ltd
SHG:605168
|
-0.021x |
|
Shenzhen Bromake New Material Co. Ltd. A
SHE:301387
|
N/A |
|
Pebblebrook Hotel Trust
NYSE:PEB
|
0.033x |
|
CBIZ Inc
NYSE:CBZ
|
-0.013x |
|
Aether Industries Limited
NSE:AETHER
|
0.047x |
|
Zhejiang DiAn Diagnostics Co
SHE:300244
|
0.069x |
Annual Cash Flow Conversion Efficiency for Henan Lingrui Pharmaceutical Co Ltd (1999–2025)
The table below shows the annual cash flow conversion efficiency of Henan Lingrui Pharmaceutical Co Ltd from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Henan Lingrui Pharmaceutical Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥3.44 Billion ≈ $502.78 Million |
CN¥553.88 Million ≈ $81.05 Million |
0.161x | -43.31% |
| 2024-12-31 | CN¥3.08 Billion ≈ $450.74 Million |
CN¥875.86 Million ≈ $128.17 Million |
0.284x | -2.17% |
| 2023-12-31 | CN¥2.80 Billion ≈ $409.54 Million |
CN¥813.43 Million ≈ $119.03 Million |
0.291x | -10.94% |
| 2022-12-31 | CN¥2.56 Billion ≈ $374.38 Million |
CN¥834.91 Million ≈ $122.17 Million |
0.326x | -11.77% |
| 2021-12-31 | CN¥2.29 Billion ≈ $334.60 Million |
CN¥845.69 Million ≈ $123.75 Million |
0.370x | +90.63% |
| 2020-12-31 | CN¥2.32 Billion ≈ $339.80 Million |
CN¥450.53 Million ≈ $65.93 Million |
0.194x | -4.30% |
| 2019-12-31 | CN¥2.22 Billion ≈ $324.92 Million |
CN¥450.15 Million ≈ $65.87 Million |
0.203x | -2.67% |
| 2018-12-31 | CN¥2.09 Billion ≈ $306.49 Million |
CN¥436.25 Million ≈ $63.84 Million |
0.208x | +333.20% |
| 2017-12-31 | CN¥2.20 Billion ≈ $322.52 Million |
CN¥105.97 Million ≈ $15.51 Million |
0.048x | +60.53% |
| 2016-12-31 | CN¥2.11 Billion ≈ $309.08 Million |
CN¥63.26 Million ≈ $9.26 Million |
0.030x | -67.07% |
| 2015-12-31 | CN¥1.72 Billion ≈ $252.28 Million |
CN¥156.82 Million ≈ $22.95 Million |
0.091x | +14.19% |
| 2014-12-31 | CN¥1.56 Billion ≈ $228.39 Million |
CN¥124.32 Million ≈ $18.19 Million |
0.080x | -38.36% |
| 2013-12-31 | CN¥984.89 Million ≈ $144.12 Million |
CN¥127.27 Million ≈ $18.62 Million |
0.129x | +483.53% |
| 2012-12-31 | CN¥696.97 Million ≈ $101.99 Million |
CN¥15.43 Million ≈ $2.26 Million |
0.022x | -62.59% |
| 2011-12-31 | CN¥684.01 Million ≈ $100.09 Million |
CN¥40.49 Million ≈ $5.92 Million |
0.059x | +1163.14% |
| 2010-12-31 | CN¥709.69 Million ≈ $103.85 Million |
CN¥-3.95 Million ≈ $-578.20K |
-0.006x | -102.71% |
| 2009-12-31 | CN¥645.69 Million ≈ $94.48 Million |
CN¥132.61 Million ≈ $19.40 Million |
0.205x | +158.23% |
| 2008-12-31 | CN¥549.72 Million ≈ $80.44 Million |
CN¥43.72 Million ≈ $6.40 Million |
0.080x | +188.20% |
| 2007-12-31 | CN¥579.24 Million ≈ $84.76 Million |
CN¥15.99 Million ≈ $2.34 Million |
0.028x | -49.82% |
| 2006-12-31 | CN¥486.67 Million ≈ $71.21 Million |
CN¥26.76 Million ≈ $3.92 Million |
0.055x | -21.07% |
| 2005-12-31 | CN¥479.80 Million ≈ $70.21 Million |
CN¥33.43 Million ≈ $4.89 Million |
0.070x | -7.89% |
| 2004-12-31 | CN¥469.45 Million ≈ $68.70 Million |
CN¥35.51 Million ≈ $5.20 Million |
0.076x | +43.63% |
| 2003-12-31 | CN¥451.69 Million ≈ $66.10 Million |
CN¥23.79 Million ≈ $3.48 Million |
0.053x | -68.38% |
| 2002-12-31 | CN¥416.74 Million ≈ $60.98 Million |
CN¥69.41 Million ≈ $10.16 Million |
0.167x | +1861.90% |
| 2001-12-31 | CN¥401.79 Million ≈ $58.79 Million |
CN¥3.41 Million ≈ $499.14K |
0.008x | -5.34% |
| 2000-12-31 | CN¥408.46 Million ≈ $59.77 Million |
CN¥3.66 Million ≈ $536.06K |
0.009x | -88.42% |
| 1999-12-31 | CN¥62.08 Million ≈ $9.08 Million |
CN¥4.81 Million ≈ $703.65K |
0.077x | -- |
About Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orth… Read more